Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cancer antigen 125 level after a bilateral salpingo-oophorectomy: what is the contribution of the ovary to the cancer antigen 125 level?

Menopause (New York, N.Y.) - 1 Feb 2011

van Altena Anne M, Holtsema Hilda, Hendriks Jan C, Massuger Leon F, de Hullu Joanne A

Abstract excerpt

OBJECTIVE: Serum cancer antigen (CA) 125 is the only biomarker used frequently in women with or at risk for ovarian cancer. However, the same reference level is used before and after (prophylactic) bilateral salpingo-oophorectomy (BSO). We evaluated the effect of BSO on CA125 level in BRCA mutation carriers and tested which factors interact with the change in CA125 level. METHODS: All women who participated in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CA-125 Antigen
Share to Carcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fallopian Tubes

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Menopause

Share to Ovariectomy

Source

Identifiers

PMID: 20861755
DOI: 10.1097/gme.0b013e3181ecfb51

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Cancer antigen 125 level after a bilateral salpingo-oophorectomy: what is the contribution of the ovary to the cancer antigen 125 level?PMID 20861755Read ↗

The reduction of CA 125 serum levels in BRCA 1/2 mutation carriers after risk-reducing salpingo-oophorectomy is only partially associated with surgery: a prospective cohort, other biomarker controlled, study.Semantic proximity Read ↗

Baseline and post prophylactic tubal-ovarian surgery CA125 levels in BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

Malignancies following bilateral salpingo-oophorectomy (BSO).Semantic proximity Read ↗

Use of hormone replacement therapy after risk-reducing salpingo-oophorectomy.Semantic proximity Read ↗

Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer.Semantic proximity Read ↗

Estimating the ovarian cancer CA-125 preclinical detectable phase, in-vivo tumour doubling time, and window for detection in early stage: an exploratory analysis of UKCTOCSSemantic proximity Read ↗

Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT.Semantic proximity Read ↗

Nadir CA-125 Is Prognostic for Recurrence, but Not for Survival in Patients With Ovarian CancerSemantic proximity Read ↗

Impact of risk-reducing salpingo-oophorectomy on lipid determinants, HbA1c and CRP.Semantic proximity Read ↗

Weight gain after oophorectomy among women with a BRCA1 or BRCA2 mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.